Newly identified gene mutation adds to melanoma risk
|
|
A major international study has identified a novel gene mutation that appears to increase the risk of both inherited and sporadic cases of malignant melanoma, the most deadly form of skin cancer. The identified mutation occurs in the gene encoding MITF, a transcription factor that induces the production of several important proteins in melanocytes, the cells in which melanoma originates. While previous research has suggested that MITF may act as a melanoma oncogene, the current study identifies a mechanism by which MITF mutation could increase melanoma risk.
The report from researchers from the U.S., the U.K. and Australia is receiving advance online publication in Nature. It is expected to appear in a print issue along with a study from French researchers finding that the same mutation increased the risk for the most common form of kidney cancer, for melanoma or for both tumors.
“We previously knew that MITF is a master regulator for production of the pigment melanin; and several years ago we identified a chemical modification, called sumoylation, that represses MITF activity,” says David Fisher, MD, PhD, chief of Dermatology at Massachusetts General Hospital (MGH), director of the MGH Cutaneous Biology Research Center and co-senior author of the Nature paper. “The currently discovered mutation appears to block sumoylation of MITF, and the resulting overactivity of MITF significantly increases melanoma risk.”
While around 10 percent of patients with melanoma report a family history of the disease, true hereditary melanoma, involving multiple cases across many generations, probably accounts for 1 percent or less of all cases, says co-senior author Hensin Tsao, MD, PhD, of MGH Dermatology and the Wellman Center for Photomedicine. “Most cutaneous melanomas arise as a result of interaction between environmental factors such as excessive sun exposure and more common, inherited low- to moderate-risk gene variants – such as in the red-hair gene MC1R and this novel variant in MITF.”
The investigators began the current study by sequencing the genome of a melanoma patient from a family in which eight cases of melanoma had been reported across three generations – four in first-degree relatives of the patient – but with neither of the two identified high-risk mutations. Among several novel variants they found, the investigators focused on a mutation in MITF, since it had previously been identified as a potential melanoma oncogene. Genetic material was available from six additional affected members of this family, and the same MITF mutation – designated E318K – was found in two of them.
To further analyze the role of this mutation in melanoma risk, the researchers genotyped samples from several large studies conducted in the U.K. and Australia involving more than 15,000 individuals. The E318K mutation occurred more frequently in individuals with melanoma than in healthy controls, and was even more common among families with two or three cases of melanoma. Analysis of the mutation’s effects on MITF function confirmed that it reduces sumoylation and increases the transcription of some but not all genes controlled by MITF. The E318K mutation was also associated with increased numbers of the common skin moles called nevi, a recognized risk factor for melanoma, and with a reduced likelihood of blue eye color.
“This MITF variant doubles the background risk for melanoma, which is approximately the same risk increase conferred by severe sunburns; however, an important aspect of this study is the elegant demonstration of how the E318K change affects MITF function ” says Tsao. “Furthermore, documenting this moderate level of risk required thousands of cases and controls worldwide, a testament to the unique collaborative nature of this study and the potential utility of next-generation sequencing for gene discovery.”
Fisher adds, “We now need to better understand exactly how this mutation causes melanocytes to become cancerous. That information might help us discover other oncogenes as well as find treatment strategies to block the cancer-promoting activity and kill melanoma cells.” Fisher is the Wigglesworth Professor of Dermatology, and Tsao is an associate professor of Dermatology at Harvard Medical School.
###
Co-lead authors of the Nature paper are Satoru Yokoyama from Fisher’s laboratory in the MGH Cutaneous Biology Research Center; Susan Woods, Glen Boyle, Lauren Aoude, and Stuart MacGregor, Queensland Institute of Medical Research (QIMR), Australia; and Victoria Zismann, Translational Genomics Research Institute (TGen), Phoenix, Arizona. Additional co-senior authors are Jeffrey Trent, TGen; Nicholas Hayward, QIMR; and Kevin Brown, National Cancer Institute. Support for the study includes major grants from the National Institutes of Health, the Dr. Miriam and Sheldon G. Adelson Medical Research Foundation, and the Melanoma Research Alliance.
Celebrating the 200th anniversary of its founding in 1811, Massachusetts General Hospital (http://www.massgeneral.org) is the original and largest teaching hospital of Harvard Medical School. MGH conducts the largest hospital-based research program in the United States, with an annual research budget of nearly $700 million and major research centers in AIDS, cardiovascular research, cancer, computational and integrative biology, cutaneous biology, human genetics, medical imaging, neurodegenerative disorders, regenerative medicine, reproductive biology, systems biology, transplantation biology and photomedicine.
###
Sue McGreevey
.(JavaScript must be enabled to view this email address)
617-724-2764
Massachusetts General Hospital
Print Version
Tell-a-Friend comments powered by Disqus
